Really helpful list of abstracts to watch at #ESMO24 - thanks Oncology Brothers

1st phase III trial of an ADC vs docetaxel in a biomarker selected population Tusamitamab Ravtansine targets CEACAM5, overexpressed in 25% of non sq NSCLC CARMEN LC03 did not meet the primary endpoints PFS and OS. #WCLC24

Adjuvant Durvalumab after resection of stage IB~IIIA NSCLC does not improve DFS. No predictive effect of PD-L1 expression as in KN-091/PEARLS (adj pembro): Biology of micrometastatic disease differs from matched primary tumor? Confirms that neoadjuvant is the way to go. #ESMO24

YES! De-escalation trials matter and should be much more supported by payers! Very preliminary results from the Dutch non inferiority trial DEDICATION-1 are reassuring. In France, the PULSE trial has the same hypothesis, opens soon in Belgium, Spain, Estonia and Greece! #ESMO24

.Martin Reck updates AGEAN biomarkers and outcomes. N=283 available. ctDNA clearance associated with pCR and improved EFS. Pre surgical ctDNA clearance warrants further study as a predictive biomarker #ESMO24

Great to see new options in development for #ALK #NSCLC patients #LCSM #ESMO24 - thanks for sharing JessicaJLinMD

Thanks for sharing Katsuaki Maehara 🇯🇵 #ESMO24

For those implementing the MARIPOSA-2 regimen of amivantamab + chemotherapy in #EGFR NSCLC post-osimertinib, highlighting the SKIPPirr study from #WCLC24 by Dr. gilberto lopes: dexamethasone 8mg po bid starting 2d before IV amivantamab led to IRR rate of 22.5% (historically 67.4%).

Interesting. 2 key messages ▶️concurrent IO does not improve survival in both SCLC and NSCLC (as per PACIFIC 2 trial)- mechanism? 🤔 ▶️Higher survival with BD RT (mOS 35.4 m, 95% CI: 32.3-NR ) vs OD RT (mOS 28.3 m 95% CI: 21.7 - 40.6; HR=1.44, 95% CI: 1.10-1.89) as per ADRIATIC

It is truly an exciting time for small-cell #lungcancer and we are witnessing the #research, and #treatment strategies progress at an impressive speed. In light of the encouraging #SCLC data presented at #ASCO2024 and #WCLC2024, I am happy to share our NatureRevClinOncol review

NUT Carcinoma is an ultra-rare entity with a NUTM1 fusion, diagnosed by a simple IHC NUT+ (can look like a squamous lung cancer in a never smoker pt). Previously known as midline carcinoma, its prognosis is extremely poor. Lurbinectedin appears promising! annalsofoncology.org/article/S0923-…

Sad to see this decision. We do need a regulatory path to approval (eg N-of-1 trials) for rare #NSCLC subsets

🚨 Out in Clinical Lung Cancer, just in time for #LungCancerAwareness month! We discuss "#Biomarker Landscape of #ADCs and #Bispecifics in Clinical Trials for #lcsm" 🔍🧬 Are we taking a biomarker-driven approach for these novel agents? ➡️We found 69.6% of ongoing clinical trials

This is what an effective screening program looks like and how it saves lives. Keep up the great work, Mike!

A must-read Review on the ever-evolving field of #EGFR mut #NSCLC in@NatRevClinOncol highlighting: ➡️Strategies to improve on 1L 3rd Gen TKI mono therapy ➡️ Ways to tackle resistance post-Osi ➡️Perioperative landscape Xiuning Le MD PhD Daniel Tan Suresh S. Ramalingam, MD, FASCO IASLC #LCSM #some

Perioperative osimertinib for resectable #EGFR NSCLC in the single institution NORA trial JTO & JTO CRR from Jii Bum Lee et al. After 56d of neoadjuvant osimertinib, RR 44%, MPR 24%, pCR rate 0%. mDFS not yet reached after 31m. jto.org/article/S1556-…

Value of different kind of 🩸#LiquidBiopsies in guiding care of our patients with #cancer. Different platforms. Pros and cons to each approach. Boils down to the cancer type and clinical question. One size doesn’t fit all. ➕to assess treatment response. dailynews.ascopubs.org/do/ctdna-assay…

How to reduce toxicity with amivantamab - phase II COCOON trial meets primary endpoint. Proactive prophylactic dermatologic regimen reduced skin and nail toxicity. Doxycycline po bid, clindamycin topical, chlorhexidine wash, ceramides-based moisturizer innovativemedicine.jnj.com/newsroom/cocoo…

Long-term Survival Case of SCLC Transformation After Osimertinib Resistance in EGFR-mutant NSCLC: Benefits from Chemo-immunotherapy Combined with Anti-angiogenic Therapy Followed by Osimertinib Rechallenge sciencedirect.com/science/articl…

Results from osimertinib plus savolitinib in #EGFR NSCLC with #MET amplification after progression on osimertinib (cohort in ORCHARD trial) now JTO & JTO CRR (n=32). RR 47%, DOR 14.5m, PFS 7.6m, OS 20.7m. jto.org/article/S1556-…